Chembio Diagnostics Inc, Medford, NY, has announced plans to build a US sales and marketing team after notifying Alere Inc of the termination of its US Stat-Pak distribution agreement.
John Sperzel, Chembio Diagnostics
A leader in point-of-care diagnostic tests for infectious diseases, Chembio granted Alere the exclusive right to distribute its Stat-Pak HIV assays in the US market in 2006, under Alere’s Clearview brand.
Effective June 3, 2014, Alere’s US distribution rights for Stat-Pak will be terminated in accordance with the terms of the agreement. Following the effective date, Chembio will begin marketing and selling the FDA-approved and CLIA-waived Chembio HIV 1/2 Stat-Pak assay in the US market.
Chembio develops, manufactures, licenses, and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio markets its HIV Stat-Pak line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors.
Chembio has developed a patented point-of-care test platform technology, the dual path platform (DPP) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP.
Chembio’s plan to build a sales and marketing team to serve US customers and distribution partners was announced in conjunction with the termination of its distribution agreement with Alere.
“We intend to initially market the Chembio DPP HIV 1/2 Oral Fluid test and the Chembio DPP HIV-Syphilis test to moderately complex sites via the Chembio US sales and marketing team,” said John Sperzel, president and CEO of Chembio. “We have already hired a director of sales, senior director of global marketing, and started hiring sales representatives.”
For more information, visit Chembio Diagnostics.
